52-Week Data from PaTHway Trial Further Supports TransCon PTH in Hypoparathyroidism
Data from the open-label extension portion of the phase 3 PaTHway trial detail the long-term effects of TransCon PTH use among people with chronic hypoparathyroidism.
Source: hcplive.com